Hematology

Thirty-month Complete Response in Follicular Lymphoma: A New Endpoint?

Thirty-month Complete Response in Follicular Lymphoma: A New Endpoint?

By

Thirty-month complete response is an accurate predictive endpoint for progression-free survival in follicular lymphoma clinical trials.

Multiple Myeloma: Adding Bortezomib to Lenalidomide, Dexamethasone as Front-line Treatment

Multiple Myeloma: Adding Bortezomib to Lenalidomide, Dexamethasone as Front-line Treatment

By

VRd may be an effective front-line treatment for patients with multiple myeloma.

Expected PCO2 (Winters)

A calculator for determining Expected PCO2 (Winters).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs